Abstracts tagged "Cutaneous lupus erythematosus"

Abstract Number: 1398 • 2016 ACR/ARHP Annual Meeting
Practice-Based Differences Between Pediatric Rheumatologists and Dermatologists Caring for Children with Discoid Lupus
Lisa Arkin¹, Kaveh Ardalan², Heather Brandling-Bennett³, Yvonne Chiu⁴, Benjamin Chong⁵, Megan Curran⁶, Raegan Hunt⁷, Amy Paller⁸, Victoria P. Werth^9,10, Marisa Klein-Gitelman⁶, Emily von Scheven¹¹ and for the CARRA SLE workgroup, ¹Department of Dermatology and Pediatrics;, University of Wisconsin School of Medicine & Public Health/American Family Children’s Hospital, Madison, WI, ²Division of Rheumatology; Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Dermatology; Department of Pediatrics, Seattle Children’s Hospital/University of Washington School of Medicine, Seattle, WA, ⁴Department of Dermatology and Pediatrics, Medical College of Wisconsin / Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁶Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Departments of Dermatology and Pediatrics, Baylor College of Medicine / Texas Children’s Hospital, Houston, TX, ⁸Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Dermatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Discoid lupus erythematosus (DLE) is rare in children. There are no consensus guidelines for management or screening for evolution to systemic lupus erythematosus (SLE).…
Abstract Number: 1782 • 2015 ACR/ARHP Annual Meeting
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Naoto Yokogawa¹, Toshiya Takahashi², Toshiaki Sato³ and Naohisa Yokota⁴, ¹on behalf of Japanese Hydroxychloroquine Study Group, Japan, Japan, ²Sanofi K.K., Tokyo, Japan, ³Sanofi.KK, Tokyo, Japan, ⁴Sanofi KK, Tokyo, Japan
Background/Purpose: In Japan hydroxychloroquine (HCQ) is still unavailable due to the banning of chloroquine in 1974 following allegations that it caused severe retinopathy. Therefore, a…
Abstract Number: 1608 • 2013 ACR/ARHP Annual Meeting
A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
Victoria P. Werth¹, David Fiorentino², Stanley B. Cohen³, David Fivenson⁴, Chris Hansen⁵, Steve Zoog⁶, Greg Arnold⁷, Christine Wang⁸, Michael Boedigheimer⁶, Andrew Welcher⁶, James Chung⁶, Barbara Sullivan⁶ and David A. Martin⁹, ¹Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ²Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Metroplex Clinical Research Center, Dallas, TX, ⁴David Fivenson, MD, Dermatology, PLLC, Ann Arbor, MI, ⁵University of Utah School of Medicine, Salt Lake City, UT, ⁶Amgen, Thousand Oaks, CA, ⁷Medical Sciences, Amgen, Thousand Oaks, CA, ⁸Biostatistics, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: Discoid Lupus Erythematosus (DLE) is the most common form of chronic cutaneous LE (CCLE) and develops in up to a quarter of SLE patients.…
Abstract Number: 1401 • 2012 ACR/ARHP Annual Meeting
Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus
Kristen Foering¹, Aileen Y. Chang², Evan W. Piette², Joyce Okawa³ and Victoria P. Werth⁴, ¹Dermatology, University of Pennsylvania, Philadelphia VAMC, Philadelphia, PA, ²Dermatology/2nd Fl, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Photosensitivity (PS) is one of the most common manifestations of systemic lupus erythematosus (SLE), and is 1 of only 11 criteria used to make…
Abstract Number: 947 • 2012 ACR/ARHP Annual Meeting
The Impact of Dyspigmentation and Scarring in Cutaneous Lupus On Quality of Life
Saroj M. Verma¹, Joyce Okawa², Kathleen Propert³ and Victoria P. Werth⁴, ¹Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Patients with more severe cutaneous lupus activity have poorer quality of life. The main objective of the current study was to evaluate the impact…
Abstract Number: 608 • 2012 ACR/ARHP Annual Meeting
Association of Discoid Lupus with Other Clinical Manifestations Among Patients with Systemic Lupus Erythematosus
Joseph F. Merola¹, Christina Iversen², Jose A. Gomez-Puerta², Tabatha Norton², Hsun Tsao², Peter H. Schur², Elena M. Massarotti², Bonnie L. Bermas³ and Karen H. Costenbader², ¹Rheumatology, Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Prior studies suggest that cutaneous discoid lupus (DLE) is a marker for less severe disease with a low frequency of nephritis and end-stage renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].